AMRI announced today that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing, whose parent company, Shire, is a global company that focuses its business on behavioral health, gastro intestinal diseases, rare diseases and regenerative medicine.
The agreement extends a previously existing agreement between the two companies.
The terms of the agreement are confidential.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
Ineos has completed a major £30 million investment at its Hull manufacturing site, converting the facility to run on clean-burning hydrogen instead of natural gas. This results in a 75% cut in carbon emissions.
Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.
